Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
Journal
Nature reviews. Cardiology
ISSN: 1759-5010
Titre abrégé: Nat Rev Cardiol
Pays: England
ID NLM: 101500075
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
accepted:
22
09
2021
pubmed:
12
11
2021
medline:
13
4
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis and contribute to the development of novel diagnostic and therapeutic strategies to further reduce the risk of cardiovascular disease. Macrophages have key roles in atherosclerosis progression and, therefore, macrophage-associated pathological processes are important targets for both diagnostic imaging and novel therapies for atherosclerosis. In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in atherosclerotic plaques with the use of rationally designed nanoparticles. We review the latest progress in nanoparticle-based imaging modalities that can specifically target macrophages. Using novel molecular imaging technology, these modalities enable the identification of advanced atherosclerotic plaques and the assessment of the therapeutic efficacy of medical interventions. Additionally, we provide novel perspectives on how macrophage-targeting nanoparticles can deliver a broad range of therapeutic payloads to atherosclerotic lesions. These nanoparticles can suppress pro-atherogenic macrophage processes, leading to improved resolution of inflammation and stabilization of plaques. Finally, we propose future opportunities for novel diagnostic and therapeutic strategies and provide solutions to challenges in this area for the purpose of accelerating the clinical translation of nanomedicine for the treatment of atherosclerotic vascular disease.
Identifiants
pubmed: 34759324
doi: 10.1038/s41569-021-00629-x
pii: 10.1038/s41569-021-00629-x
pmc: PMC8580169
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
228-249Subventions
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146134
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL158097
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL156362
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127464
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118676
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141853
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL162367
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL087123
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL159012
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL137229
Pays : United States
Informations de copyright
© 2021. Springer Nature Limited.
Références
Virani, S. S. et al. Heart disease and stroke statistics-2021 update: a report from the American heart association. Circulation 143, e254–e743 (2021).
pubmed: 33501848
doi: 10.1161/CIR.0000000000000950
Tabas, I., Williams, K. J. & Borén, J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 116, 1832–1844 (2007).
pubmed: 17938300
doi: 10.1161/CIRCULATIONAHA.106.676890
Ross, R. Atherosclerosis — an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
pubmed: 9887164
doi: 10.1056/NEJM199901143400207
Mestas, J. & Ley, K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med. 18, 228–232 (2008).
pubmed: 19185814
pmcid: 2650852
doi: 10.1016/j.tcm.2008.11.004
Glass, C. K. & Witztum, J. L. Atherosclerosis. The road ahead. Cell 104, 503–516 (2001).
pubmed: 11239408
doi: 10.1016/S0092-8674(01)00238-0
Moore, K. J. & Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341–355 (2011). This review discusses the central roles of monocyte-derived macrophages in both early atherogenesis and advanced plaque progression.
pubmed: 21529710
pmcid: 3111065
doi: 10.1016/j.cell.2011.04.005
Doran, A. C., Yurdagul, A. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).
pubmed: 31822793
doi: 10.1038/s41577-019-0240-6
Yurdagul, A., Doran, A. C., Cai, B., Fredman, G. & Tabas, I. A. Mechanisms and consequences of defective efferocytosis in atherosclerosis. Front. Cardiovasc. Med. 4, 86 (2018).
pubmed: 29379788
pmcid: 5770804
doi: 10.3389/fcvm.2017.00086
Kasikara, C., Doran, A. C., Cai, B. & Tabas, I. The role of non-resolving inflammation in atherosclerosis. J. Clin. Invest. 128, 2713–2723 (2018).
pubmed: 30108191
pmcid: 6025992
doi: 10.1172/JCI97950
Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. Circ. Res. 114, 1852–1866 (2014). This review discusses mechanisms of atherosclerotic plaque initiation and progression and the concepts of plaque activity, burden and vulnerability.
pubmed: 24902970
doi: 10.1161/CIRCRESAHA.114.302721
Lieb, W., Enserro, D. M., Larson, M. G. & Vasan, R. S. Residual cardiovascular risk in individuals on lipid-lowering treatment: quantifying absolute and relative risk in the community. Open Heart 5, e000722 (2018).
pubmed: 29387429
pmcid: 5786911
doi: 10.1136/openhrt-2017-000722
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D. & Wong, N. D. The evolving understanding and approach to residual cardiovascular risk management. Front. Cardiovasc. Med. 7, 88 (2020).
pubmed: 32478100
pmcid: 7237700
doi: 10.3389/fcvm.2020.00088
Lobatto, M. E., Fuster, V., Fayad, Z. A. & Mulder, W. J. M. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10, 835–852 (2011).
pubmed: 22015921
pmcid: 3623275
doi: 10.1038/nrd3578
Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotech. 2, 751–760 (2007).
doi: 10.1038/nnano.2007.387
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M. & Peer, D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat. Commun. 9, 1410 (2018).
pubmed: 29650952
pmcid: 5897557
doi: 10.1038/s41467-018-03705-y
Chen, W., Glackin, C. A., Horwitz, M. A. & Zink, J. I. Nanomachines and other caps on mesoporous silica nanoparticles for drug delivery. Acc. Chem. Res. 52, 1531–1542 (2019).
pubmed: 31082188
doi: 10.1021/acs.accounts.9b00116
Combadière, C. et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C
pubmed: 18347211
doi: 10.1161/CIRCULATIONAHA.107.745091
Sager, H. B. et al. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci. Transl Med. 8, 342ra80 (2016).
pubmed: 27280687
pmcid: 5125383
doi: 10.1126/scitranslmed.aaf1435
Stoneman, V. et al. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 100, 884–893 (2007).
pubmed: 17322176
pmcid: 2040259
doi: 10.1161/01.RES.0000260802.75766.00
Hoeksema, M. A., Stöger, J. L. & De Winther, M. P. J. Molecular pathways regulating macrophage polarization: Implications for atherosclerosis. Curr. Atheroscler. Rep. 14, 254–263 (2012).
pubmed: 22407286
pmcid: 3348484
doi: 10.1007/s11883-012-0240-5
Depuydt, M. A. C. et al. Microanatomy of the human atherosclerotic plaque by single-cell transcriptomics. Circ. Res. 127, 1437–1455 (2020).
pubmed: 32981416
pmcid: 7641189
doi: 10.1161/CIRCRESAHA.120.316770
Stöger, J. L. et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 225, 461–468 (2012).
pubmed: 23078881
doi: 10.1016/j.atherosclerosis.2012.09.013
Chinetti-Gbaguidi, G. et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ. Res. 108, 985–995 (2011).
pubmed: 21350215
pmcid: 3319502
doi: 10.1161/CIRCRESAHA.110.233775
Kennedy, M. A. et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1, 121–131 (2005).
pubmed: 16054053
doi: 10.1016/j.cmet.2005.01.002
Oram, J. F., Lawn, R. M., Garvin, M. R. & Wade, D. P. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J. Biol. Chem. 275, 34508–34511 (2000).
pubmed: 10918070
doi: 10.1074/jbc.M006738200
Wang, N., Lan, D., Chen, W., Matsuura, F. & Tall, A. R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl Acad. Sci. USA 101, 9774–9779 (2004).
pubmed: 15210959
pmcid: 470750
doi: 10.1073/pnas.0403506101
Wang, N., Silver, D. L., Costet, P. & Tall, A. R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J. Biol. Chem. 275, 33053–33058 (2000).
pubmed: 10918065
doi: 10.1074/jbc.M005438200
Chawla, A. et al. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7, 161–171 (2001).
pubmed: 11172721
doi: 10.1016/S1097-2765(01)00164-2
Tangirala, R. K. et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99, 11896–11901 (2002).
pubmed: 12193651
pmcid: 129365
doi: 10.1073/pnas.182199799
Naik, S. U. et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation 113, 90–97 (2006).
pubmed: 16365197
doi: 10.1161/CIRCULATIONAHA.105.560177
Joseph, S. B. et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 99, 7604–7609 (2002).
pubmed: 12032330
pmcid: 124297
doi: 10.1073/pnas.112059299
Fessler, M. B. The challenges and promise of targeting the liver X receptors for treatment of inflammatory disease. Pharmacol. Ther. 181, 1–12 (2018).
pubmed: 28720427
doi: 10.1016/j.pharmthera.2017.07.010
He, C. et al. Cultured macrophages transfer surplus cholesterol into adjacent cells in the absence of serum or high-density lipoproteins. Proc. Natl Acad. Sci. USA 117, 10476–10483 (2020).
pubmed: 32354992
pmcid: 7229689
doi: 10.1073/pnas.1922879117
Tall, A. R. & Yvan-Charvet, L. Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15, 104–116 (2015).
pubmed: 25614320
pmcid: 4669071
doi: 10.1038/nri3793
Westerterp, M. et al. Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice. Circ. Res. 112, 1456–1465 (2013).
pubmed: 23572498
doi: 10.1161/CIRCRESAHA.113.301086
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017). Results of a clinical trial that shows that anti-inflammatory therapy against IL-1β can reduce the risk of cardiovascular events in patients with previous myocardial infarction.
pubmed: 28845751
doi: 10.1056/NEJMoa1707914
Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497–2505 (2019).
pubmed: 31733140
doi: 10.1056/NEJMoa1912388
Hansson, G. K., Libby, P. & Tabas, I. Inflammation and plaque vulnerability. J. Intern. Med. 278, 483–493 (2015).
pubmed: 26260307
pmcid: 5082111
doi: 10.1111/joim.12406
Virmani, R., Burke, A. P., Farb, A. & Kolodgie, F. D. Pathology of the vulnerable plaque. J. Am. Coll. Cardiol. 47, C13–C18 (2006).
pubmed: 16631505
doi: 10.1016/j.jacc.2005.10.065
Galis, Z. S., Sukhova, G. K., Lark, M. W. & Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994).
pubmed: 7989608
pmcid: 330083
doi: 10.1172/JCI117619
Quillard, T. et al. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 31, 2464–2472 (2011).
pubmed: 21903941
pmcid: 3200308
doi: 10.1161/ATVBAHA.111.231563
Herman, M. P. et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104, 1899–1904 (2001).
pubmed: 11602491
doi: 10.1161/hc4101.097419
Boyle, J. J., Weissberg, P. L. & Bennett, M. R. Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 23, 1553–1558 (2003).
pubmed: 12869351
doi: 10.1161/01.ATV.0000086961.44581.B7
Doran, A. C. et al. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis. J. Clin. Invest. 127, 4075–4089 (2017).
pubmed: 28972541
pmcid: 5663361
doi: 10.1172/JCI94735
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K. & Kovanen, P. T. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat. Rev. Cardiol. 16, 389–406 (2019).
pubmed: 30846875
pmcid: 6727648
Schrijvers, D. M., De Meyer, G. R. Y., Kockx, M. M., Herman, A. G. & Martinet, W. Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25, 1256–1261 (2005).
pubmed: 15831805
doi: 10.1161/01.ATV.0000166517.18801.a7
Fredman, G. & Tabas, I. Boosting inflammation resolution in atherosclerosis: the next frontier for therapy. Am. J. Pathol. 187, 1211–1221 (2017).
pubmed: 28527709
pmcid: 5455064
doi: 10.1016/j.ajpath.2017.01.018
Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl Med. 7, 275ra20 (2015).
pubmed: 25695999
pmcid: 4397585
doi: 10.1126/scitranslmed.aaa1065
Yurdagul, A. et al. Macrophage metabolism of apoptotic cell-derived arginine promotes continual efferocytosis and resolution of injury. Cell Metab. 31, 518–533.e10 (2020).
pubmed: 32004476
pmcid: 7173557
doi: 10.1016/j.cmet.2020.01.001
Bertrand, N. et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat. Commun. 8, 777 (2017).
pubmed: 28974673
pmcid: 5626760
doi: 10.1038/s41467-017-00600-w
Walkey, C. D. & Chan, W. C. W. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41, 2780–2799 (2012).
pubmed: 22086677
doi: 10.1039/C1CS15233E
Tao, W. et al. siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice. Sci. Transl Med. 12, eaay1063 (2020). This study shows that macrophage-targeted siRNA nanoparticles can restore efferocytic capacity of atherosclerotic lesional macrophages and, therefore, reduce plaque burden in a preclinical model of advanced atherosclerosis.
pubmed: 32718990
pmcid: 7476570
doi: 10.1126/scitranslmed.aay1063
Wang, Y. et al. Biomimetic nanotherapies: red blood cell based core–shell structured nanocomplexes for atherosclerosis management. Adv. Sci. 6, 1900172 (2019).
doi: 10.1002/advs.201900172
Wei, X. et al. Nanoparticle functionalization with platelet membrane enables multifactored biological targeting and detection of atherosclerosis. ACS Nano 12, 109–116 (2018).
pubmed: 29216423
doi: 10.1021/acsnano.7b07720
Ma, Q. et al. Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy. J. Control. Rel. 329, 445–453 (2021).
doi: 10.1016/j.jconrel.2020.11.064
Gao, C. et al. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines. Nat. Commun. 11, 2622 (2020).
pubmed: 32457361
pmcid: 7251120
doi: 10.1038/s41467-020-16439-7
Wu, G. et al. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment. Angew. Chem. Int. Ed. 59, 4068–4074 (2020).
doi: 10.1002/anie.201913700
Binderup, T. et al. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci. Transl Med. 11, eaaw7736 (2019).
pubmed: 31434756
pmcid: 7328283
doi: 10.1126/scitranslmed.aaw7736
Lameijer, M. et al. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat. Biomed. Eng. 2, 279–292 (2018).
pubmed: 30936448
pmcid: 6447057
doi: 10.1038/s41551-018-0221-2
Terashima, M. et al. Human ferritin cages for imaging vascular macrophages. Biomaterials 32, 1430–1437 (2011).
pubmed: 21074263
doi: 10.1016/j.biomaterials.2010.09.029
Uchida, M. et al. Protein cage nanoparticles bearing the LyP-1 peptide for enhanced imaging of macrophage-rich vascular lesions. ACS Nano 5, 2493–2502 (2011).
pubmed: 21391720
pmcid: 3082619
doi: 10.1021/nn102863y
Tang, J. et al. Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proc. Natl Acad. Sci. USA 113, E6731–E6740 (2016).
pubmed: 27791119
pmcid: 5098679
doi: 10.1073/pnas.1609629113
Flores, A. M. et al. Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis. Nat. Nanotechnol. 15, 154–161 (2020). This study utilizes ‘Trojan horse’ single-walled carbon nanotubes to reactivate efferocytic capacity of macrophages by inhibiting the antiphagocytic CD47–SIRPα signalling axis.
pubmed: 31988506
pmcid: 7254969
doi: 10.1038/s41565-019-0619-3
Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005–1010 (2011).
pubmed: 21983520
pmcid: 3212614
doi: 10.1038/nbt.1989
Kim, Y. et al. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc. Natl Acad. Sci. USA 111, 1078–1083 (2014).
pubmed: 24395808
pmcid: 3903216
doi: 10.1073/pnas.1322725111
Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).
pubmed: 27834398
doi: 10.1038/nrc.2016.108
Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016).
pubmed: 27100066
pmcid: 5199136
doi: 10.1021/acsnano.6b01114
Yu, M. et al. Targeted nanotherapeutics encapsulating liver X receptor agonist GW3965 enhance antiatherogenic effects without adverse effects on hepatic lipid metabolism in Ldlr
doi: 10.1002/adhm.201700313
Stein-Merlob, A. F. et al. Atheroma susceptible to thrombosis exhibit impaired endothelial permeability in vivo as assessed by nanoparticle-based fluorescence molecular imaging. Circ. Cardiovasc. Imaging 10, e005813 (2017).
pubmed: 28487316
pmcid: 5509162
doi: 10.1161/CIRCIMAGING.116.005813
Beldman, T. J. et al. Nanoparticle-aided characterization of arterial endothelial architecture during atherosclerosis progression and metabolic therapy. ACS Nano 13, 13759–13774 (2019).
pubmed: 31268670
pmcid: 6933811
doi: 10.1021/acsnano.8b08875
Poller, W. C. et al. Uptake of citrate-coated iron oxide nanoparticles into atherosclerotic lesions in mice occurs via accelerated transcytosis through plaque endothelial cells. Nano Res. 9, 3437–3452 (2016).
doi: 10.1007/s12274-016-1220-9
Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).
pubmed: 31932672
doi: 10.1038/s41563-019-0566-2
Majmudar, M. D. et al. Polymeric nanoparticle PET/MR imaging allows macrophage detection in atherosclerotic plaques. Circ. Res. 112, 755–761 (2013).
pubmed: 23300273
pmcid: 3586287
doi: 10.1161/CIRCRESAHA.111.300576
Li, C. et al. Site-specific microRNA-33 antagonism by pH-responsive nanotherapies for treatment of atherosclerosis via regulating cholesterol efflux and adaptive immunity. Adv. Funct. Mater. 30, 2002131 (2020).
doi: 10.1002/adfm.202002131
Senders, M. L. et al. Nanobody-facilitated multiparametric PET/MRI phenotyping of atherosclerosis. JACC Cardiovasc. Imaging 12, 2015–2026 (2019).
pubmed: 30343086
doi: 10.1016/j.jcmg.2018.07.027
Narita, Y. et al. Macrophage-targeted, enzyme-triggered fluorescence switch-on system for detection of embolism-vulnerable atherosclerotic plaques. J. Control. Rel. 302, 105–115 (2019).
doi: 10.1016/j.jconrel.2019.03.025
Beldman, T. J. et al. Hyaluronan nanoparticles selectively target plaque-associated macrophages and improve plaque stability in atherosclerosis. ACS Nano 11, 5785–5799 (2017).
pubmed: 28463501
pmcid: 5492212
doi: 10.1021/acsnano.7b01385
Qiao, R. et al. Molecular imaging of vulnerable atherosclerotic plaques in vivo with osteopontin-specific upconversion nanoprobes. ACS Nano 11, 1816–1825 (2017).
pubmed: 28121134
doi: 10.1021/acsnano.6b07842
Sun, X. et al. In vivo targeting and imaging of atherosclerosis using multifunctional virus-like particles of simian virus 40. Nano Lett. 16, 6164–6171 (2016).
pubmed: 27622963
doi: 10.1021/acs.nanolett.6b02386
Nie, S. et al. Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles. J. Control. Rel. 220, 61–70 (2015).
doi: 10.1016/j.jconrel.2015.10.004
Nguyen, M. A. et al. Delivery of microRNAs by chitosan nanoparticles to functionally alter macrophage cholesterol efflux in vitro and in vivo. ACS Nano 13, 6491–6505 (2019).
pubmed: 31125197
doi: 10.1021/acsnano.8b09679
Lu, J. et al. Biofunctional polymer-lipid hybrid high-density lipoprotein-mimicking nanoparticles loading anti-miR155 for combined antiatherogenic effects on macrophages. Biomacromolecules 18, 2286–2295 (2017).
pubmed: 28738148
doi: 10.1021/acs.biomac.7b00436
Gao, W. et al. H
pubmed: 29629115
doi: 10.1039/C7SC03582A
Behzadi, S. et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218–4244 (2017).
pubmed: 28585944
pmcid: 5593313
doi: 10.1039/C6CS00636A
Weissleder, R., Nahrendorf, M. & Pittet, M. J. Imaging macrophages with nanoparticles. Nat. Mater. 13, 125–138 (2014).
pubmed: 24452356
doi: 10.1038/nmat3780
Schmitz, S. A. et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14, 355–361 (2001).
pubmed: 11599058
doi: 10.1002/jmri.1194
Kool, M. E. et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453–2458 (2003).
doi: 10.1161/01.CIR.0000068315.98705.CC
Morishige, K. et al. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis. Circulation 122, 1707–1715 (2010).
pubmed: 20937980
pmcid: 3003265
doi: 10.1161/CIRCULATIONAHA.109.891804
Qiao, H. et al. MRI/optical dual-modality imaging of vulnerable atherosclerotic plaque with an osteopontin-targeted probe based on Fe
pubmed: 27788352
doi: 10.1016/j.biomaterials.2016.10.011
Cheng, D. et al. Detection of vulnerable atherosclerosis plaques with a dual-modal single-photon-emission computed tomography/magnetic resonance imaging probe targeting apoptotic macrophages. ACS Appl. Mater. Interfaces 7, 2847–2855 (2015).
pubmed: 25569777
doi: 10.1021/am508118x
Trivedi, R. A. et al. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler. Thromb. Vasc. Biol. 26, 1601–1606 (2006). Together with Kool et al. (2003), this study shows that ultrasmall superparamagnetic particles of iron oxide-enhanced MRI can be used for in vivo detection of macrophages in human atherosclerotic plaques.
pubmed: 16627809
doi: 10.1161/01.ATV.0000222920.59760.df
Tang, T. Y. et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 53, 2039–2050 (2009).
pubmed: 19477353
doi: 10.1016/j.jacc.2009.03.018
Nowogrodzki, A. The world’s strongest MRI machines are pushing human imaging to new limits. Nature 563, 24–26 (2018).
pubmed: 30382222
doi: 10.1038/d41586-018-07182-7
Amirbekian, V. et al. Detecting and assessing macrophages in vivo to evalute atherosclerosis noninvasively using molecular MRI. Proc. Natl Acad. Sci. USA 104, 961–966 (2007).
pubmed: 17215360
pmcid: 1766334
doi: 10.1073/pnas.0606281104
Xing, H. et al. Ultrasmall NaGdF
pubmed: 24677351
doi: 10.1002/adma.201305222
Grobner, T. & Prischl, F. C. Immune cell screening of a nanoparticle library improves. Kidney Int. 72, 260–264 (2007).
pubmed: 17507905
doi: 10.1038/sj.ki.5002338
Van Heeswijk, R. B. et al. Fluorine MR imaging of inflammation in atherosclerotic plaque in vivo. Radiology 275, 421–429 (2015).
pubmed: 25496216
doi: 10.1148/radiol.14141371
Akazawa, K. et al. Perfluorocarbon-based
doi: 10.1002/anie.201810363
Budoff, M. J. et al. Assessment of coronary artery disease by cardiac computed tomography. Circulation 114, 1761–1791 (2006).
pubmed: 17015792
doi: 10.1161/CIRCULATIONAHA.106.178458
Hyafil, F. et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat. Med. 13, 636–641 (2007).
pubmed: 17417649
doi: 10.1038/nm1571
Ding, J. et al. CT/fluorescence dual-modal nanoemulsion platform for investigating atherosclerotic plaques. Biomaterials 34, 209–216 (2013).
pubmed: 23069709
doi: 10.1016/j.biomaterials.2012.09.025
Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
pubmed: 23126252
doi: 10.1056/NEJMoa1206797
Fayad, Z. A. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 378, 1547–1559 (2011).
pubmed: 21908036
pmcid: 4151875
doi: 10.1016/S0140-6736(11)61383-4
Cormode, D. P. et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology 256, 774–782 (2010).
pubmed: 20668118
pmcid: 2923725
doi: 10.1148/radiol.10092473
Danad, I., Fayad, Z. A., Willemink, M. J. & Min, J. K. New applications of cardiac computed tomography. JACC Cardiovasc. Imaging 8, 710–723 (2015).
pubmed: 26068288
pmcid: 4467470
doi: 10.1016/j.jcmg.2015.03.005
Rudd, J. H. F. et al. Imaging atherosclerotic plaque inflammation with [
pubmed: 12057982
doi: 10.1161/01.CIR.0000020548.60110.76
Keliher, E. J. et al. Polyglucose nanoparticles with renal elimination and macrophage avidity facilitate PET imaging in ischaemic heart disease. Nat. Commun. 8, 14064 (2017).
pubmed: 28091604
pmcid: 5241815
doi: 10.1038/ncomms14064
Pérez-Medina, C. et al. In vivo PET imaging of HDL in multiple atherosclerosis models. JACC Cardiovasc. Imaging 9, 950–961 (2016).
pubmed: 27236528
pmcid: 5589956
doi: 10.1016/j.jcmg.2016.01.020
Wang, Y. et al. Optical/MRI dual-modality imaging of M1 macrophage polarization in atherosclerotic plaque with MARCO-targeted upconversion luminescence probe. Biomaterials 219, 119378 (2019).
pubmed: 31382209
doi: 10.1016/j.biomaterials.2019.119378
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04237064 (2020).
Ge, X. et al. A non-invasive nanoprobe for in vivo photoacoustic imaging of vulnerable atherosclerotic plaque. Adv. Mater. 32, 2000037 (2020).
doi: 10.1002/adma.202000037
Gao, W. et al. A redox-responsive self-assembled nanoprobe for photoacoustic inflammation imaging to assess atherosclerotic plaque vulnerability. Anal. Chem. 91, 1150–1156 (2019).
pubmed: 30497260
doi: 10.1021/acs.analchem.8b04912
Nahrendorf, M. et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117, 379–387 (2008).
pubmed: 18158358
doi: 10.1161/CIRCULATIONAHA.107.741181
Withana, N. P. et al. Dual-modality activity-based probes as molecular imaging agents for vascular inflammation. J. Nucl. Med. 57, 1583–1590 (2016).
pubmed: 27199363
pmcid: 5367444
doi: 10.2967/jnumed.115.171553
Swirski, F. K. & Nahrendorf, M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339, 161–166 (2013).
pubmed: 23307733
pmcid: 3891792
doi: 10.1126/science.1230719
Swirski, F. K. et al. Ly-6C
pubmed: 17200719
pmcid: 1716211
doi: 10.1172/JCI29950
Potteaux, S. et al. Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe
pubmed: 21505265
pmcid: 3083793
doi: 10.1172/JCI43802
Hilgendorf, I., Swirski, F. K. & Robbins, C. S. Monocyte fate in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 35, 272–279 (2015).
pubmed: 25538208
doi: 10.1161/ATVBAHA.114.303565
Lutgens, E. et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391–404 (2010).
pubmed: 20100871
pmcid: 2822598
doi: 10.1084/jem.20091293
Seijkens, T. T. P. et al. Targeting CD40-induced TRAF6 signaling in macrophages reduces atherosclerosis. J. Am. Coll. Cardiol. 71, 527–542 (2018). Together with Lameijer et al. (2018), this study shows that nanoimmunotherapy can inhibit monocyte recruitment and be used to treat atherosclerosis by targeting CD40–TRAF6 signalling.
pubmed: 29406859
pmcid: 5800892
doi: 10.1016/j.jacc.2017.11.055
Katsuki, S. et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 129, 896–906 (2014).
pubmed: 24305567
doi: 10.1161/CIRCULATIONAHA.113.002870
Krohn-Grimberghe, M. et al. Nanoparticle-encapsulated siRNAs for gene silencing in the haematopoietic stem-cell niche. Nat. Biomed. Eng. 4, 1076–1089 (2020).
pubmed: 33020600
pmcid: 7655681
doi: 10.1038/s41551-020-00623-7
Robbins, C. S. et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19, 1166–1172 (2013).
pubmed: 23933982
pmcid: 3769444
doi: 10.1038/nm.3258
Boada, C. et al. Rapamycin-loaded biomimetic nanoparticles reverse vascular inflammation. Circ. Res. 126, 25–37 (2020).
pubmed: 31647755
doi: 10.1161/CIRCRESAHA.119.315185
Dou, Y. et al. Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Biomaterials 143, 93–108 (2017).
pubmed: 28778000
doi: 10.1016/j.biomaterials.2017.07.035
Zhang, R. et al. A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases. Biomaterials 230, 119605 (2020).
pubmed: 31740099
doi: 10.1016/j.biomaterials.2019.119605
Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343, 425–430 (1990).
pubmed: 1967820
doi: 10.1038/343425a0
Tang, J. et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci. Adv. 1, e1400223 (2015).
pubmed: 26295063
pmcid: 4539616
doi: 10.1126/sciadv.1400223
Duivenvoorden, R. et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3065 (2014). Together with Tang et al (2015), this study presents data that demonstrate that statin-loaded HDL-like nanoparticles can effectively decrease macrophage burden in atherosclerotic plaques.
pubmed: 24445279
doi: 10.1038/ncomms4065
Hossaini Nasr, S. et al. Effective atherosclerotic plaque inflammation inhibition with targeted drug delivery by hyaluronan conjugated atorvastatin nanoparticles. Nanoscale 12, 9541–9556 (2020).
pubmed: 32314997
doi: 10.1039/D0NR00308E
Kim, Y. et al. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 7, 9975–9983 (2013).
pubmed: 24079940
pmcid: 4104519
doi: 10.1021/nn4039063
Alaarg, A. et al. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J. Control. Rel. 262, 47–57 (2017).
doi: 10.1016/j.jconrel.2017.07.013
Kim, H. et al. Affinity-driven design of cargo-switching nanoparticles to leverage a cholesterol-rich microenvironment for atherosclerosis therapy. ACS Nano 14, 6519–6531 (2020).
pubmed: 32343121
pmcid: 8543299
doi: 10.1021/acsnano.9b08216
Kojima, Y. et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature 536, 86–90 (2016).
pubmed: 27437576
pmcid: 4980260
doi: 10.1038/nature18935
Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
pubmed: 30380386
pmcid: 8058634
doi: 10.1056/NEJMoa1807315
Thorp, E., Cui, D., Schrijvers, D. M., Kuriakose, G. & Tabas, I. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of Apoe
pubmed: 18451332
pmcid: 2575060
doi: 10.1161/ATVBAHA.108.167197
Soehnlein, O. & Libby, P. Targeting inflammation in atherosclerosis — from experimental insights to the clinic. Nat. Rev. Drug Discov. 20, 589–610 (2021). This review describes the role of inflammation in atherogenesis and summarizes strategies of inflammation targeting for atherosclerosis treatment.
pubmed: 33976384
pmcid: 8112476
doi: 10.1038/s41573-021-00198-1
Tabas, I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat. Rev. Immunol. 10, 36–46 (2010).
pubmed: 19960040
doi: 10.1038/nri2675
Ridker, P. M. et al. Low-dose methotrexate for the prevention of atherosclerotic events. N. Engl. J. Med. 380, 752–762 (2019).
pubmed: 30415610
doi: 10.1056/NEJMoa1809798
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04616872 (2020).
Kim, M. et al. Targeted delivery of anti-inflammatory cytokine by nanocarrier reduces atherosclerosis in Apo E
pubmed: 31645012
doi: 10.1016/j.biomaterials.2019.119550
Kamaly, N. et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl Acad. Sci. USA 110, 6506–6511 (2013).
pubmed: 23533277
pmcid: 3631648
doi: 10.1073/pnas.1303377110
Stigliano, C. et al. Methotraxate-loaded hybrid nanoconstructs target vascular lesions and inhibit atherosclerosis progression in ApoE
doi: 10.1002/adhm.201601286
Di Francesco, V. et al. Modulating lipoprotein transcellular transport and atherosclerotic plaque formation in ApoE
pubmed: 32805983
pmcid: 7453397
doi: 10.1021/acsami.0c12202
Nakashiro, S. et al. Pioglitazone-incorporated nanoparticles prevent plaque destabilization and rupture by regulating monocyte/macrophage differentiation in ApoE
pubmed: 26821947
doi: 10.1161/ATVBAHA.115.307057
Wang, Y., Wang, G. Z., Rabinovitch, P. S. & Tabas, I. Macrophage mitochondrial oxidative stress promotes atherosclerosis and nuclear factor-κB-mediated inflammation in macrophages. Circ. Res. 114, 421–433 (2014).
pubmed: 24297735
doi: 10.1161/CIRCRESAHA.114.302153
Wang, Y. et al. Targeted therapy of atherosclerosis by a broad-spectrum reactive oxygen species scavenging nanoparticle with intrinsic anti-inflammatory activity. ACS Nano 12, 8943–8960 (2018).
pubmed: 30114351
doi: 10.1021/acsnano.8b02037
Guo, J. et al. Cyclodextrin-derived intrinsically bioactive nanoparticles for treatment of acute and chronic inflammatory diseases. Adv. Mater. 31, 1904607 (2019).
doi: 10.1002/adma.201904607
McCarthy, J. R., Korngold, E., Weissleder, R. & Jaffer, F. A. A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. Small 6, 2041–2049 (2010).
pubmed: 20721949
pmcid: 3018665
doi: 10.1002/smll.201000596
Kharlamov, A. N. & Gabinsky, J. L. Plasmonic photothermic and stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling. Rejuvenation Res. 15, 222–230 (2012).
pubmed: 22533437
doi: 10.1089/rej.2011.1305
Kharlamov, A. N. et al. Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial. Nanoscale 7, 8003–8015 (2015).
pubmed: 25864858
doi: 10.1039/C5NR01050K
Kosuge, H. et al. Near infrared imaging and photothermal ablation of vascular inflammation using single-walled carbon nanotubes. J. Am. Heart Assoc. 1, e002568 (2012).
pubmed: 23316318
pmcid: 3540665
doi: 10.1161/JAHA.112.002568
Qin, J. et al. Gold nanorods as a theranostic platform for in vitro and in vivo imaging and photothermal therapy of inflammatory macrophages. Nanoscale 7, 13991–14001 (2015).
pubmed: 26228112
doi: 10.1039/C5NR02521D
Wang, X. et al. Differential phagocytosis-based photothermal ablation of inflammatory macrophages in atherosclerotic disease. ACS Appl. Mater. Interfaces 11, 41009–41018 (2019).
pubmed: 31599564
doi: 10.1021/acsami.9b12258
Chen, W., Cheng, C. A. & Zink, J. I. Spatial, temporal, and dose control of drug delivery using noninvasive magnetic stimulation. ACS Nano 13, 1292–1308 (2019).
pubmed: 30633500
Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: The importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255–2264 (2005).
pubmed: 16141399
doi: 10.1161/01.ATV.0000184783.04864.9f
Rosenson, R. S. et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 125, 1905–1919 (2012).
pubmed: 22508840
pmcid: 4159082
doi: 10.1161/CIRCULATIONAHA.111.066589
Khera, A. V. et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364, 127–135 (2011).
pubmed: 21226578
pmcid: 3030449
doi: 10.1056/NEJMoa1001689
Feinberg, M. W. & Moore, K. J. MicroRNA regulation of atherosclerosis. Cir. Res. 118, 703–720 (2016).
doi: 10.1161/CIRCRESAHA.115.306300
Hong, C. & Tontonoz, P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat. Rev. Drug Discov. 13, 433–444 (2014).
pubmed: 24833295
doi: 10.1038/nrd4280
Zhang, X. Q. et al. Nanoparticles containing a liver X receptor agonist inhibit inflammation and atherosclerosis. Adv. Healthc. Mater. 4, 228–236 (2015).
pubmed: 25156796
doi: 10.1002/adhm.201400337
Gadde, S. et al. Development of therapeutic polymeric nanoparticles for the resolution of inflammation. Adv. Healthc. Mater. 3, 1448–1456 (2014).
pubmed: 24659608
pmcid: 4160375
doi: 10.1002/adhm.201300688
Guo, Y. et al. Synthetic high-density lipoprotein-mediated targeted delivery of liver X receptors agonist promotes atherosclerosis regression. EBioMedicine 28, 225–233 (2018).
pubmed: 29361501
doi: 10.1016/j.ebiom.2017.12.021
Liao, X. et al. Macrophage autophagy plays a protective role in advanced atherosclerosis. Cell Metab. 15, 545–553 (2012).
pubmed: 22445600
pmcid: 3322248
doi: 10.1016/j.cmet.2012.01.022
Song, Y. et al. Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE
pubmed: 30171903
doi: 10.1016/j.nano.2018.08.002
Lewis, D. R. et al. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc. Natl Acad. Sci. USA 112, 2693–2698 (2015).
pubmed: 25691739
pmcid: 4352838
doi: 10.1073/pnas.1424594112
US Food and Drug Administration. Highlights of prescribing information: Fenoglide (fenofibrate) tablets (FDA, 1993).
Aday, A. W. & Ridker, P. M. Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease. Front. Cardiovasc. Med. 6, 16 (2019).
pubmed: 30873416
pmcid: 6403155
doi: 10.3389/fcvm.2019.00016
van der Valk, F. M. et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine 11, 1039–1046 (2015).
pubmed: 25791806
doi: 10.1016/j.nano.2015.02.021
Bentzon, J. F. & Falk, E. Atherosclerotic lesions in mouse and man: Is it the same disease? Curr. Opin. Lipidol. 21, 434–440 (2010).
pubmed: 20683327
doi: 10.1097/MOL.0b013e32833ded6a
Zadelaar, S. et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. 27, 1706–1721 (2007).
pubmed: 17541027
doi: 10.1161/ATVBAHA.107.142570
Westerterp, M. et al. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. Arter. Thromb. Vasc. Biol. 26, 2552–2559 (2006).
doi: 10.1161/01.ATV.0000243925.65265.3c
Marso, S. P. et al. Plaque composition and clinical outcomes in acute coronary syndrome patients with metabolic syndrome or diabetes. JACC Cardiovasc. Imaging 5 (Suppl. 3), S42–S52 (2012).
pubmed: 22421230
doi: 10.1016/j.jcmg.2012.01.008
Tawakol, A. et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose- positron emission tomography/computed tomography feasibility study. J. Am. Coll. Cardiol. 62, 909–917 (2013).
pubmed: 23727083
doi: 10.1016/j.jacc.2013.04.066
Mulder, W. J. M., Jaffer, F. A., Fayad, Z. A. & Nahrendorf, M. Imaging and nanomedicine in inflammatory atherosclerosis. Sci. Transl. Med. 6, 239sr1 (2014).
pubmed: 24898749
pmcid: 4110972
doi: 10.1126/scitranslmed.3005101
Cosco, E. D. et al. Shortwave infrared polymethine fluorophores matched to excitation lasers enable non-invasive, multicolour in vivo imaging in real time. Nat. Chem. 12, 1123–1130 (2020).
pubmed: 33077925
pmcid: 7680456
doi: 10.1038/s41557-020-00554-5
Chen, W. et al. Shortwave infrared imaging with J-aggregates stabilized in hollow mesoporous silica nanoparticles. J. Am. Chem. Soc. 141, 12475–12480 (2019).
pubmed: 31353894
pmcid: 6746239
doi: 10.1021/jacs.9b05195
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03473223 (2021). This is an ongoing, large-scale, phase III clinical trial that will test whether HDL-like nanoparticles can reduce the risk of major adverse cardiovascular events in patients with acute coronary syndrome.
Gille, A., D’Andrea, D., Tortorici, M. A., Hartel, G. & Wright, S. D. CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients. Arter. Thromb. Vasc. Biol. 38, 953–963 (2018).
doi: 10.1161/ATVBAHA.118.310538
Ma, R. et al. Amorphous silica nanoparticles accelerated atherosclerotic lesion progression in ApoE
pubmed: 33008402
pmcid: 7531166
doi: 10.1186/s12989-020-00380-0
Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotechnol. 11, 986–994 (2016).
pubmed: 27668795
pmcid: 5198777
doi: 10.1038/nnano.2016.168
Stadler, N., Lindner, R. A. & Davies, M. J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 24, 949–954 (2004).
pubmed: 15001454
doi: 10.1161/01.ATV.0000124892.90999.cb
Williams, J. W. et al. Single cell RNA sequencing in atherosclerosis research. Circ. Res. 126, 1112–1126 (2020).
pubmed: 32324494
pmcid: 7185048
doi: 10.1161/CIRCRESAHA.119.315940
Nilsson, J. & Hansson, G. K. Vaccination strategies and immune modulation of atherosclerosis. Circ. Res. 126, 1281–1296 (2020).
pubmed: 32324498
doi: 10.1161/CIRCRESAHA.120.315942
Hansson, G. K. & Nilsson, J. Developing a vaccine against atherosclerosis. Nat. Rev. Cardiol. 17, 451–452 (2020).
pubmed: 32587346
doi: 10.1038/s41569-020-0407-7
Chyu, K. Y. & Shah, P. K. In pursuit of an atherosclerosis vaccine chasing the Holy Grail. Circ. Res. 123, 1121–1123 (2018).
pubmed: 30359192
doi: 10.1161/CIRCRESAHA.118.313842
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines-a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261–279 (2018).
pubmed: 29326426
pmcid: 5906799
doi: 10.1038/nrd.2017.243
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246
doi: 10.1056/NEJMoa2034577
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04148833 (2020).
Zheng, K. H. et al. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis 311, 13–19 (2020).
pubmed: 32919280
doi: 10.1016/j.atherosclerosis.2020.08.004
Nicholls, S. J. et al. Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT trial: a randomized clinical trial. JAMA Cardiol. 3, 806–814 (2018).
pubmed: 30046837
pmcid: 6233637
doi: 10.1001/jamacardio.2018.2112
Kharlamov, A. N. et al. Plasmonic photothermal therapy of atherosclerosis with nanoparticles: long-term outcomes and safety in NANOM-FIM trial. Futur. Cardiol. 13, 345–363 (2017). Together with Kharlamov et al. (2015), this is the first-in-human trial that demonstrates that plasmonic photothermal therapy can reduce atherosclerotic plaque burden and major adverse cardiovascular events.
doi: 10.2217/fca-2017-0009
Nicholls, S. J. et al. Effect of serial infusions of CER-001, a pre-β high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial. JAMA Cardiol. 3, 815–822 (2018).
pubmed: 30046828
pmcid: 6233644
doi: 10.1001/jamacardio.2018.2121
Tardif, J. C. et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. 35, 3277–3286 (2014).
pubmed: 24780501
pmcid: 4258222
doi: 10.1093/eurheartj/ehu171
Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290, 2292–2300 (2003).
pubmed: 14600188
doi: 10.1001/jama.290.17.2292
Zheng, K. H. et al. HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis 251, 381–388 (2016).
pubmed: 27263077
doi: 10.1016/j.atherosclerosis.2016.05.038
Zheng, K. H. et al. Plaque permeability assessed with DCE-MRI associates with USPIO uptake in patients with peripheral artery disease. JACC Cardiovasc. Imaging 12, 2081–2083 (2019).
pubmed: 31202746
doi: 10.1016/j.jcmg.2019.04.014
Smits, L. P. et al. Evaluation of ultrasmall superparamagnetic iron-oxide (USPIO) enhanced MRI with ferumoxytol to quantify arterial wall inflammation. Atherosclerosis 263, 211–218 (2017).
pubmed: 28662398
doi: 10.1016/j.atherosclerosis.2017.06.020
Tang, T. et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke 37, 2266–2270 (2006).
pubmed: 16917091
doi: 10.1161/01.STR.0000236063.47539.99
Howarth, S. P. S. et al. Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: a comparison of symptomatic and asymptomatic individuals. Eur. J. Radiol. 70, 555–560 (2009).
pubmed: 18356000
doi: 10.1016/j.ejrad.2008.01.047